Soleno Therapeutics, Inc.

BST:6XC1 Stock Report

Market Cap: €23.0m

Soleno Therapeutics Management

Management criteria checks 2/4

Soleno Therapeutics' CEO is Anish Bhatnagar, appointed in Feb 2014, has a tenure of 8.5 years. total yearly compensation is $4.38M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €45.35K. The average tenure of the management team and the board of directors is 5.6 years and 5.9 years respectively.

Key information

Anish Bhatnagar

Chief executive officer

US$4.4m

Total compensation

CEO salary percentage12.3%
CEO tenure8.5yrs
CEO ownership0.2%
Management average tenure5.6yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Anish Bhatnagar's remuneration changed compared to Soleno Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$4mUS$538k

-US$31m

Sep 30 2021n/an/a

-US$31m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$3mUS$504k

-US$25m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$822kUS$470k

-US$31m

Sep 30 2019n/an/a

-US$16m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$952kUS$460k

-US$12m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$1mUS$446k

-US$12m

Sep 30 2017n/an/a

-US$13m

Jun 30 2017n/an/a

-US$11m

Mar 31 2017n/an/a

-US$9m

Dec 31 2016US$959kUS$460k

-US$10m

Sep 30 2016n/an/a

-US$8m

Jun 30 2016n/an/a

-US$10m

Mar 31 2016n/an/a

-US$7m

Dec 31 2015US$1mUS$435k

-US$10m

Compensation vs Market: Anish's total compensation ($USD4.38M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Anish's compensation has increased whilst the company is unprofitable.

CEO

Anish Bhatnagar (52 yo)

8.5yrs

Tenure

US$4,375,442

Compensation

Dr. Anish Bhatnagar, M.D. has been Chief Executive Officer and Director of Soleno Therapeutics, Inc. since February 6, 2014 and serves as its President and Chief Operating Officer. Dr. Bhatnagar served as...

Leadership Team

NamePositionTenureCompensationOwnership
Anish Bhatnagar
President8.5yrsUS$4.38m0.20%
€ 45.4k
James MacKaness
Chief Financial Officer1.8yrsUS$392.00k0.055%
€ 12.7k
Kristen Yen
Vice President of Clinical Operationsno dataUS$821.67k0.020%
€ 4.7k
Patricia Hirano
Vice President of Regulatory Affairs3.6yrsUS$920.83k0.067%
€ 15.3k
Anthony Wondka
Senior VP & GM7.6yrsUS$270.00kno data
Neil Cowen
Senior Vice President of Drug Developmentno datano datano data

5.6yrs

Average Tenure

56yo

Average Age

Experienced Management: 6XC1's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anish Bhatnagar
President8.5yrsUS$4.38m0.20%
€ 45.4k
Ernest Mario
Independent Chairman15yrsUS$176.36k2.2%
€ 505.9k
William Harris
Independent Director8.2yrsUS$156.39k0.11%
€ 25.3k
Gwen Melincoff
Independent Director3.3yrsUS$144.89k0.0082%
€ 1.9k
Thomas Casale
Member of Advisory Boardno datano datano data
Andrew Sinclair
Independent Director3.7yrsUS$96.39k0%
€ 0
Robert Christensen
Member of Advisory Boardno datano datano data
Vinod Bhutani
Member of Advisory Boardno datano datano data
Birgitte Volck
Independent Director3.2yrsUS$147.39k0.087%
€ 20.0k
Glenis Scadding
Member of Advisory Boardno datano datano data
David Stevenson
Member of Advisory Boardno datano datano data

5.9yrs

Average Tenure

62yo

Average Age

Experienced Board: 6XC1's board of directors are considered experienced (5.9 years average tenure).